Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This article discusses the BJUI's strategies to support urology-related clinical trials but reports no new experimental results; the authors emphasize the importance of rigorous trial design and reporting standards.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.

This study found that intradermal injections of cultured autologous dermal sheath cup cells for androgenetic alopecia showed hair loss stabilization at 24 months without serious adverse effects and a sustained response in some participants.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

This study conducted in Egypt evaluated antifungal treatments for sheep with dermatophytosis, finding that tioconazole cream, clotrimazole spray, and fluconazole capsules were effective, with tioconazole cream providing an easily applicable and highly effective topical option, achieving a 100% cure rate in the short term.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

This study observed that topically applied 2% minoxidil solution significantly increased hair counts in men with early male pattern alopecia over 24 weeks, with no serious safety concerns.

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

This study found that 1mg/day oral finasteride significantly improved androgenetic alopecia in Chinese men, with a higher efficacy rate compared to placebo and minimal adverse effects.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

The hypothesis in this study is that probiotic supplementation could improve hormonal, metabolic, inflammatory, and antioxidant markers in individuals with PCOS compared to a placebo, although results are not yet reported.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

This article outlines a randomized trial to evaluate whether preoperative botulinum toxin administration can improve hair transplantation outcomes by reducing ischemia-induced graft failure.

This study outlines a randomized trial investigating the effects of botulinum toxin administered before hair transplantation to potentially improve outcomes by enhancing blood flow and reducing graft failure due to ischemia in androgenetic alopecia patients.

This study outlines a randomized trial to assess if administering botulinum toxin before hair transplantation can improve outcomes by enhancing blood flow and reducing ischemia-induced graft failure in patients with androgenetic alopecia.

In this study, the researchers found that after initial hair regrowth with ritlecitinib in patients with severe alopecia areata, it took a median of 93 days to reach clinical trial-defined scalp hair regrowth, with those responding earlier showing faster progression to desired outcomes.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This article corrects a duplication error in a previous publication and reports no new research findings.

This article reports no new research findings and corrects the affiliation for Dr. Shao-Wen Li in a previous publication.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

In this study involving 15 women with alopecia, subcutaneous scalp injections of platelet-rich plasma every four weeks for three sessions led to increased hair and hair follicle density at 24 weeks, with common side effects being local swelling and pain.

This study found that platelet-rich plasma may be more effective and satisfactory than topical clobetasol for treating lichen planopilaris over six months.

In this study, oral minoxidil at 5 mg/day improved hair density comparably to topical minoxidil 5% in men with androgenetic alopecia over 24 weeks, offering a viable alternative for those intolerant to topical application.